Optimizing Tobacco Use Treatment for PLWHA

PHASE3RecruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
HIV/AIDSNicotine Dependence
Interventions
DRUG

Varenicline

Participants will receive open-label varenicline for 12 weeks.

DRUG

Nicotine patch

Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)

BEHAVIORAL

Standard treatment

Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.

BEHAVIORAL

Standard treatment + Managed Problem Solving (MAPS) adherence intervention

Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.

Trial Locations (2)

19104

RECRUITING

University of Pennsylvania, Philadelphia

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Northwestern University

OTHER

lead

University of Pennsylvania

OTHER

NCT04176172 - Optimizing Tobacco Use Treatment for PLWHA | Biotech Hunter | Biotech Hunter